Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1384&sort=-funder_divisions
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-funder_divisions", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1392&sort=-funder_divisions", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1385&sort=-funder_divisions", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1383&sort=-funder_divisions" }, "data": [ { "type": "Grant", "id": "10712", "attributes": { "award_id": "1I21RX004396-01", "title": "Predictors of Post-COVID Clinical and Cognitive Consequences", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-12-01", "end_date": "2024-11-30", "award_amount": null, "principal_investigator": { "id": 26765, "first_name": "Susmita", "last_name": "Chowdhuri", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1960, "ror": "", "name": "JOHN D DINGELL VA MEDICAL CENTER", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "Patients recovering from acute COVID-19 infection often suffer from a multitude of debilitating chronic physical symptoms that can last up to 6 months or more. The incidence of fatigue, cognitive impairment and respiratory symptoms are reported to be very high in the post-COVID period. The underlying pathophysiology of cognitive impairment is unclear in these patients. Notably, sleep disturbances are common during this post-COVID period, and sleep apnea has been associated with an increased risk for severe COVID infection. Thus, it is conceivable that sleep fragmentation, per se, may confer an increased risk for chronic cognitive deficits in Veterans post-COVID. Our proposed pilot project will determine if there is a link between post-COVID sleep disturbances, sleep apnea and cognitive function. Knowledge gained from our examinations may guide development of novel management pathways, i.e., mitigation of sleep disturbances may present a therapeutic strategy for alleviating chronic post-COVID cognitive impairment. Aim1 will investigate the effect of sleep duration and sleep quality on neurocognitive function in post-COVID Veterans. Aim 2 will study whether the severity of OSA determines neurocognitive function Veterans who are post-COVID. This is an observational study where we will gather retrospective as well as prospective data on the long-term effects of COVID on neurocognitive function and sleep. Our long-term goal is to enhance rehabilitation and recovery of function of Veterans suffering from post-COVID consequences that may arise due to sleep disturbances, with the ultimate objective of improving the overall health and quality of life of Veterans recovering from COVID-19 infection.", "keywords": [ "Acute", "Address", "Adverse effects", "Alleles", "Alzheimer&apos", "s Disease", "Apolipoprotein E", "Area", "Blood Coagulation Disorders", "COVID-19", "COVID-19 complications", "COVID-19 cytokine storm", "COVID-19 impact", "COVID-19 severity", "Centers for Disease Control and Prevention (U.S.)", "Chronic", "Clinical", "Cognitive", "Cognitive deficits", "Complex", "Cough Headaches", "Data", "Development", "Diagnostic", "Disease", "Dyspnea", "Encephalopathies", "Fatigue", "Functional disorder", "Future", "Genes", "Goals", "Health", "Healthcare", "Hour", "Hypoxia", "Impaired cognition", "Impairment", "Incidence", "Infection", "Inflammation", "Interleukin-6", "Knowledge", "Link", "Long COVID", "Long-Term Effects", "Memory impairment", "Mental Health", "Neurocognitive", "Neurocognitive Deficit", "Neurologic", "Neutrophilia", "Observational Study", "Obstructive Sleep Apnea", "Pathway interactions", "Patients", "Pilot Projects", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Quality of life", "Recovery", "Recovery of Function", "Rehabilitation therapy", "Reporting", "Research", "Respiratory Signs and Symptoms", "Risk", "SARS-CoV-2 infection", "Severities", "Sleep", "Sleep Apnea Syndromes", "Sleep Deprivation", "Sleep Fragmentations", "Sleep disturbances", "Symptoms", "TNF gene", "Testing", "Therapeutic", "Veterans", "Virus", "Visit", "acute infection", "brain fog", "cognitive function", "coronavirus disease", "cytokine", "disability", "factor A", "improved", "inflammatory marker", "novel", "physical conditioning", "physical symptom", "poor sleep", "post SARS-CoV-2 infection", "post-COVID-19", "prospective", "research study", "respiratory", "response", "severe COVID-19", "sleep quality", "therapeutic target", "trait" ], "approved": true } }, { "type": "Grant", "id": "10725", "attributes": { "award_id": "1IK2RX003790-01A2", "title": "Neuromodulation for Rehabilitation of Post-Stroke Fatigue: An rTMS Pilot Study", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-11-01", "end_date": "2027-10-31", "award_amount": null, "principal_investigator": { "id": 26774, "first_name": "John Harvey", "last_name": "Kindred", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1782, "ror": "", "name": "RALPH H JOHNSON VA MEDICAL CENTER", "address": "", "city": "", "state": "SC", "zip": "", "country": "United States", "approved": true }, "abstract": "The long-term goal of this proposed career development award (CDA-2) is to accelerate my training and development so that I can establish an independent line of research unraveling the causes and consequences of fatigue and to develop effective evidence-based therapies for fatigue in Veterans with neurological conditions. Before my collegiate studies, I served nine years on active duty in the United States Marine Corps and received an Honorable Discharge upon the expiration of my service contract. I completed my Ph.D. in Human Bioenergetics at Colorado State University in 2017. Upon graduation, I began a post-doctoral position at the Medical University of South Carolina working with Dr. Mark G. Bowden, PT, Ph.D. Shortly after starting my post- doc position, I acquired a WOC appointment at the Ralph H. Johnson VA Medical Center and was awarded a VA Rehabilitation Research and Development Career Development Award – 1 that began in Oct 2019. Since the beginning of my research journey, I have published 22 peer-reviewed manuscripts, 12 as the first author. My most recent publications have centered on measuring the neurophysiological state of the nervous system and relating that state to post-stroke disability. These most recent manuscripts are based on data collected at the laboratories at Ralph H. Johnson before my arrival and the co-authors include several of the members of this proposal’s mentorship team. Upon completing my CDA-1 (end date Sep 30, 2021), I have focused my attention on the neurophysiological biomarkers of post-stroke fatigue. This CDA-2 proposal will provide me with the opportunity to learn new neurophysiological assessment methods and advance my knowledge and ability to apply neuromodulatory treatments. These skills will provide me the foundation to build an independent VA- backed research program focusing on reducing the impact of fatigue in Veterans with an array of neurological conditions. The assembled mentorship team is composed of experts in post-stroke rehabilitation, neuromodulation, neuroimaging, and clinical assessment. Up to 92% of people post-stroke experience fatigue. Fatigue negatively affects physical and mental performance leading to a lower quality of life. Fatigue is also present in many other neurological populations within the Veteran community, such as traumatic brain injury, multiple sclerosis, and the newly coined phenomenon of Long-COVID. Advances in the knowledge and understanding of post-stroke fatigue are likely to lead to advances in other clinical populations within the Veteran community. The first aim is to test the effects of a well-established neuromodulatory therapy, repetitive transcranial magnetic stimulation (rTMS), on reducing the severity of post-stroke fatigue. This aim is predicated on theoretical principles obtained from the study of other neuro-psychiatric/-cognitive disorders and therapeutic attempts to reduce fatigue in other neurological illnesses. Participating Veterans will receive high-frequency rTMS to the frontal lobe, either the left prefrontal dorsolateral cortex or bilaterally to the motor cortices. These locations have been implicated in fatigue in other neurological conditions. I expect to show rTMS can be used to reduce post-stroke fatigue severity. However, the effectiveness and location of treatment may partially be dependent on individual characteristics. The second aim of the study is based on the skills and knowledge developed in the CDA-1, I plan on identifying additional neurophysiological biomarkers of fatigue. In this project, I will assess glutamatergic activity/signaling of the upper and lower extremity sensorimotor network of Veterans with and without post-stroke fatigue. I expect to show that the fatigued group will show glutamatergic dysfunction, measured by greater asymmetries in intracortical facilitation and the facilitatory response to paired associative stimulation, compared to the non-fatigued group. Identification of glutamate and related metabolites as a pathophysiological contributor to post-stroke fatigue may help in the development of new therapeutic approaches for post-stroke fatigue and fatigue in other neurological conditions.", "keywords": [ "Affect", "American Heart Association", "Anxiety", "Appointment", "Attention", "Award", "Back", "Behavior", "Bilateral", "Bioenergetics", "Biological Markers", "Caregivers", "Characteristics", "Chronic Fatigue Syndrome", "Clinical", "Clinical assessments", "Cognition Disorders", "Coin", "Colorado", "Communities", "Contract Services", "Data", "Development", "Doctor of Philosophy", "Effectiveness", "Environment", "Evidence based treatment", "FDA approved", "Fatigue", "Foundations", "Frequencies", "Functional disorder", "Glutamates", "Goals", "Human", "Individual", "Intervention", "K-Series Research Career Programs", "Knowledge", "Laboratories", "Lead", "Learning", "Left", "Lesion", "Location", "Long COVID", "Lower Extremity", "Magnetic Resonance Spectroscopy", "Manuscripts", "Measures", "Medical", "Medical center", "Mental Depression", "Mental disorders", "Mentorship", "Methods", "Motor", "Motor Cortex", "Multiple Sclerosis", "Nature", "Nervous System Physiology", "Nervous system structure", "Neuraxis", "Neurocognitive", "Neurologic", "Peer Review", "Performance", "Persons", "Pharmacology", "Physical Function", "Physical activity", "Physiologic pulse", "Pilot Projects", "Play", "Population", "Positioning Attribute", "Post-Traumatic Stress Disorders", "Postdoctoral Fellow", "Prefrontal Cortex", "Prevalence", "Psyche structure", "Publications", "Publishing", "Quality of life", "Recording of previous events", "Rehabilitation therapy", "Research", "Research Personnel", "Role", "Scientist", "Services", "Severities", "Signal Transduction", "South Carolina", "Stroke", "Structure", "System", "Testing", "Therapeutic", "Training", "Transcranial magnetic stimulation", "Traumatic Brain Injury", "United States", "Universities", "Update", "Upper Extremity", "Veterans", "Veterans Health Administration", "Work", "active duty", "base", "career", "career development", "chronic stroke", "cognitive function", "college", "cost", "disability", "effective intervention", "effective therapy", "efficacy testing", "evidence base", "experience", "expiration", "frontal lobe", "improved", "insight", "member", "military veteran", "multidisciplinary", "negative affect", "nervous system disorder", "neural circuit", "neuroimaging", "neurophysiology", "neuropsychiatry", "neuroregulation", "noninvasive brain stimulation", "novel", "novel therapeutic intervention", "post stroke", "programs", "psychologic", "rehabilitation re" ], "approved": true } }, { "type": "Grant", "id": "10730", "attributes": { "award_id": "1I01RX003984-01A1", "title": "Comparing the effectiveness of telehealth to in-person delivery of a combined metacognitive and attention training in Veterans with mTBI/PTSD", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-11-01", "end_date": "2026-10-31", "award_amount": null, "principal_investigator": { "id": 26778, "first_name": "Julia Kay", "last_name": "Waid-Ebbs", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1477, "ror": "https://ror.org/05eq41471", "name": "Veterans Health Administration", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "Background. Over 70% of Veterans with mild traumatic brain injury (mTBI), seeking services at the Veterans’ Health Administration, suffer from comorbid post-traumatic stress disorder (PTSD). These Veterans commonly experience concomitant executive dysfunction in goal setting, concentration, and attention that impairs their performance in complex daily tasks. Others and we have studied Goal Management Training (GMT) to address this problem. Collectively, the data have shown that GMT improved some aspects of executive function in mTBI/PTSD but did not restore cognition to normal during complex tasks. Goal management for performing complex tasks requires cognitive processes such as attention, and direct-attention training may be beneficial in improving cognition. GMT with attention training have been used in other studies, but those did not involve Veterans with either mTBI or mTBI/PTSD. We recently conducted a pilot study combining GMT and direct-attention training (GMT+ATT) in Veterans with mTBI and PTSD. We discovered a large treatment effect (Cohen d=2.23) in the NIH EXAMINER Executive Composite score and a significant treatment response in the NIH EXAMINER Cognitive Control subdomain and the Unstructured Task. GMT or ATT is typically administered in-person. In-person treatment can impose problems such as limited treatment access, poor cost-effectiveness, and unexpected situations (like the COVID-19 pandemic). As an alternative method, telehealth has been used increasingly to meet the need for care in Veterans living in rural areas and during the pandemic. Telehealth delivery of cognitive interventions in Veterans with mTBI or with PTSD has shown effectiveness that is comparable to that of in-person treatment. However, GMT+ATT has not been studied in these Veterans. Therefore, we have recently developed the format for telehealth delivery of GMT+ATT in Veterans with mTBI/PTSD. Our preliminary data demonstrate the feasibility of this delivery platform and similar treatment outcomes as compared to in-person therapy. Objective & Hypotheses. The objective of this randomized controlled trial is to determine and compare the effect of in-person and telehealth delivery of GMT+ATT in Veterans with mTBI/PTSD. Hypothesis 1a. In-person GMT+ATT will improve cognition vs. control group (Brain Health Workshop (BHW). Hypothesis 1b. Telehealth GMT+ATT will improve cognition vs. BHW control group Hypothesis 2. Telehealth delivery of GMT+ATT will produce response comparable to in-person treatment. Primary measure. The NIH EXAMINER executive composite score will assess overall executive function with subdomains such as complex task performance requiring goal management, as well as tests underlying cognitive control such as attention and working memory. Secondary functional measures. 1) Unstructured Task and 2) Test of Grocery Shopping Skills (ToGSS), which captures naturalistic real-world function. Exploratory Objective. To study the capability of the Attention Network Task to predict treatment response to GMT+ATT. Methods. 63 Veterans will be randomized to 10 weeks of in-person or telehealth delivery of GMT+ATT or BHW control. Outcomes will be assessed at pre-, post-, 6 month-post and 1-year post-treatment. GMT and ATT will each be provided in ten, weekly, 2-hour sessions (4hrs/week as combined). Significance. This study uses a novel combinational treatment of GMT+ATT to restore the executive and attentional processes required for complex daily tasks in Veterans with mTBI/PTSD. This work meets a key VA RR&D priority of providing quality care to Veterans. Positive study results may help shape clinical practice of cognitive rehabilitation in terms of treatment strategy, delivery platform, access to care, and means to predict treatment response. Such impacts will translate to significant cost-savings for the VA healthcare system and improvement in quality of life in Veterans.", "keywords": [ "Address", "Aftercare", "Attention", "Awareness", "COVID-19 pandemic", "Caring", "Clinical", "Cognition", "Cognitive", "Complex", "Control Groups", "Cost Savings", "Data", "Department of Defense", "Educational workshop", "Effectiveness", "Evaluation Research", "Executive Dysfunction", "Goals", "Health Services Accessibility", "Healthcare Systems", "Hour", "Impaired cognition", "Impairment", "Intervention", "Life", "Measures", "Methods", "Military Personnel", "Neuropsychology", "Outcome", "Performance", "Persons", "Pilot Projects", "Population", "Post-Traumatic Stress Disorders", "Prediction of Response to Therapy", "Problem Solving", "Process", "Protocols documentation", "Psyche structure", "Quality of Care", "Quality of life", "Randomized", "Randomized Controlled Trials", "Recommendation", "Regimen", "Rehabilitation therapy", "Reporting", "Research Design", "Services", "Shapes", "Short-Term Memory", "Task Performances", "Testing", "Training", "Translating", "Translations", "Treatment outcome", "United States Department of Veterans Affairs", "United States National Institutes of Health", "Veterans", "Veterans Health Administration", "Work", "base", "brain health", "clinical practice", "cognitive control", "cognitive process", "cognitive rehabilitation", "comorbidity", "compare effectiveness", "computerized", "cost effectiveness", "directed attention", "executive function", "experience", "flexibility", "improved", "indexing", "innovation", "instrument", "mild traumatic brain injury", "military veteran", "mind control", "neurobehavioral", "novel", "pandemic disease", "randomized controlled study", "response", "rural area", "skills", "social", "systematic review", "telehealth", "treatment effect", "treatment response", "treatment strategy" ], "approved": true } }, { "type": "Grant", "id": "10732", "attributes": { "award_id": "1I01BX006008-01", "title": "Host Genetic and Epigenetic Factors of the Progression, Comorbidities and Outcomes of Viral Infection", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-10-01", "end_date": "2026-09-30", "award_amount": null, "principal_investigator": { "id": 26780, "first_name": "Vincent Charles", "last_name": "Marconi", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1477, "ror": "https://ror.org/05eq41471", "name": "Veterans Health Administration", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "Viral infections including Human immunodeficiency virus (HIV), hepatitis C virus (HCV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have placed a substantial strain on human health and the health care system. These infections have specifically had broad impacts on veteran health in the US. Host factors influence how humans respond to infectious agents and develop adverse health outcomes after infection. Although previous genome-wide association studies (GWAS) have identified loci associated with susceptibility and progression for several infections, understanding the role of host genetic and epigenetic factors on chronic disease comorbidities, aging, and long-term outcomes in the setting of viral infections has been hampered by sample size, heterogeneous populations, and discordant measurements/definitions of key phenotypes. Recent epigenome-wide association studies (EWAS) have uncovered DNA methylation markers associated with noncommunicable diseases (NCDs, such as coronary heart disease, diabetes, heart failure, chronic kidney disease), as well as HIV infection. However, the epigenetic predictors for incident NCDs and mortality are largely unknown among people with viral infections. Viral infections (e.g., HIV) can have a substantial impact on epigenetics, which may affect long-term health outcomes. Additionally, acceleration of the epigenetic clock or age has emerged as a novel biomarker of biological aging and can predict disease outcomes and mortality. Therefore, we will systematically investigate genetic and epigenetic predictors of NCDs and mortality in the following Aims. 1) To identify genetic and epigenetic predictors of age-related morbidity and mortality as well as modification effect of HIV infection among multi-ethnic veterans; 2) To identify genetic and epigenetic factors associated with morbidity and mortality among multi- ethnic veterans with HCV infection; 3) To identify genetic and epigenetic factors of long-term comorbidities, accelerated aging and mortality, as well as mediation effect of COVID-19 among multi-ethnic veterans. Impact: Viral infections including HIV, HCV and SARS-CoV-2 broadly affects veteran’s health and reduces the quality of life (healthspan) and life expectancy (lifespan) through a range of comorbidities. The molecular mechanisms underlying the morbidity and mortality after viral infections of HIV, HCV and SARS-CoV-2 are largely unknown. The proposed genetic and epigenetic study can reveal the genetic and epigenetic factors linking viral infection (acute, chronic, and resolved) and major NCD outcomes and mortality among multi-ethnic veterans, shed lights on potential targets for new prevention and intervention, provide insights into the comorbidity and aging process for all people, and develop systematic and precision medicine strategies to improve veteran’s health.", "keywords": [ "2019-nCoV", "Acceleration", "Acute", "Affect", "Age", "Aging", "Algorithms", "Antiviral Therapy", "Biological Aging", "COVID-19 impact", "Chronic", "Chronic Disease", "Chronic Kidney Failure", "Communicable Diseases", "Congestive Heart Failure", "Coronary heart disease", "DNA Methylation", "Data", "Diabetes Mellitus", "Diagnostic", "Disease", "Disease Outcome", "Disease Progression", "Electronic Health Record", "Epigenetic Process", "Ethnic group", "Evolution", "General Population", "Genetic", "Genetic Markers", "Genetic Predisposition to Disease", "HIV", "HIV Infections", "Health", "Healthcare Systems", "Heart failure", "Hepatitis C", "Hepatitis C virus", "Human", "Human Genetics", "Human Genome", "Immune", "Immune response", "Immune system", "Immunologics", "Individual", "Infection", "Infectious Agent", "Inflammatory", "Integration Host Factors", "Intervention", "Lead", "Life Expectancy", "Light", "Link", "Liver Cirrhosis", "Liver Fibrosis", "Longevity", "Measurement", "Mediation", "Mendelian randomization", "Modeling", "Modification", "Molecular", "Morbidity - disease rate", "Multiomic Data", "Organ", "Outcome", "Pathway interactions", "Persons", "Phenotype", "Population Heterogeneity", "Predisposition", "Prevention", "Process", "Prognosis", "Quality of life", "Risk Factors", "Role", "SARS-CoV-2 infection", "Sample Size", "Site", "Stroke", "System", "Therapeutic", "Veterans", "Virus Diseases", "advanced analytics", "age related", "chronic liver disease", "comorbidity", "disorder risk", "epigenetic marker", "epigenome-wide association studies", "genetic variant", "genome wide association study", "genomic locus", "healthspan", "improved", "insight", "longitudinal analysis", "methylation biomarker", "mortality", "multi-ethnic", "multiple chronic conditions", "novel marker", "pathogen", "precision medicine", "programs", "response", "virus infection mechanism" ], "approved": true } }, { "type": "Grant", "id": "11039", "attributes": { "award_id": "1R13FD007814-01", "title": "2023 Sex Differences in Immunity Gordon Research Conference", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 27011, "first_name": "Lauren", "last_name": "Doamekpor", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-02-01", "end_date": "2024-01-31", "award_amount": 20000, "principal_investigator": { "id": 22942, "first_name": "SABRA L.", "last_name": "KLEIN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 226, "ror": "https://ror.org/05rad4t93", "name": "Gordon Research Conferences", "address": "", "city": "", "state": "RI", "zip": "", "country": "United States", "approved": true }, "abstract": "Partial support is requested for a new Gordon Research Conference (GRC) on Sex Differences in Immunity. The inaugural conference will be held April 2-7, 2023 at the Four Points Sheraton in Ventura Beach, California, The Sex Differences in Immunity GRC is a premier, international scientific conference focused on advancing the frontiers of science through the presentation of cutting-edge and unpublished research, prioritizing time for discussion after each talk and fostering informal interactions among scientists of all career stages. This is the first GRC dedicated to sex differences, and the concentration on immunity is timely given growing appreciation that biological sex, near the Los Angeles International Airport. meaning the differences between males and females caused by differential sex chromosome complement, reproductive tissues, and concentrations of sex steroids, impacts the functioning of the immune system. Although sex differences in immune function have been documented for decades, the COVID-19 pandemic considerably raised awareness about the implications The conference program includes a diverse range of speakers and discussion leaders from institutions and organizations worldwide, concentrating on the latest developments in sex differences in immunity ranging from infectious diseases and cancer to autoimmunity, inflammation, mucosal immunity, metabolomics, and genomics. Throughout the diverse sessions, there is emphasis on sex differences in responses to immunomodulatory drugs and biologics. The conference is five days long and held in a remote location to increase the sense of camaraderie and create scientific communities, with lasting collaborations and friendships. In addition to premier talks, the conference has designated time for poster sessions from individuals of all career stages, a power hour dedicated to addressing challenges to achieving equity in science among women and all underrepresented groups, and afternoon free time and communal meals to allow for informal networking opportunities with leaders in the field. of sex differences in immunity to viruses and vaccines. Underrepresented minority scientists are well represented among meeting discussion leaders, speakers, and attendees. Through conscious consideration of representation and inclusion, the Sex Differences in Immunity GRC will foster involvement of underrepresented minority individuals at all levels. Funds are requested to support registration fees for invited discussion leaders and speakers, as well as junior investigators and trainees. The meeting program is freely available on the GRC website.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "11040", "attributes": { "award_id": "1I01BX006014-01A1", "title": "Molecular Characterization of Anti-Tumor Activity Mediated by Extracellular Vesicles Derived from Natural Killer Cells", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2023-02-01", "end_date": "2027-01-31", "award_amount": null, "principal_investigator": { "id": 27012, "first_name": "JACKI", "last_name": "KORNBLUTH", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1981, "ror": "https://ror.org/014c68a74", "name": "St. Louis VA Medical Center", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true }, "abstract": "Multiple myeloma (MM) is the second most common hematological cancer in the U.S and increasing in frequency. Veterans who served in Vietnam where herbicides like Agent Orange were sprayed may have increased risk of developing MM. Early-stage disease is often asymptomatic, so patients are diagnosed late, with bone pain, kidney dysfunction and infections. Although there has been progress in developing new therapies for MM, it remains incurable. Patients initially achieve remission but ultimately relapse. The disease returns more quickly, tumor cells become more resistant to treatment and the patient’s quality of life declines. Natural killer (NK) cells kill MM cells in vitro and in vivo. Clinical trials using NK cell-based immunotherapy are ongoing but not widely available. Several drugs for MM (bortezomib, carfilzomib, lenalidomide) sensitize MM cells to NK-mediated lysis and/or enhance NK killing activity. However, challenges remain. Therefore, new treatments are needed to extend survival and increase durability of remission in relapsed/refractory patients and those ineligible for front-line therapy. My laboratory developed NK3.3, the only normal human NK cell line. It was cloned from peripheral blood NK cells and kills an array of tumor cells. As NK3.3 cells grow in culture, they release small membrane-bound extracellular vesicles (EVs). We demonstrated that purified NK3.3 EVs kill MM cell lines and primary patient samples, without harming normal cells. NK3.3 EVs also kill drug-resistant and cancer stem cells (CSC). There are many advantages to using NK3.3 EVs for cancer treatment. They can be generated in large quantities, are stable, and can be frozen and thawed without loss of function. EVs are resistant to the hypoxic tumor microenvironment and unlike cellular therapy, do not induce a detrimental cytokine storm. NK3.3-derived EVs may provide the advantages of NK cell therapy without the challenges of expanding cells and side effects. The goal of these studies is to establish the feasibility of using NK3.3-derived EVs for MM treatment. We developed a murine xenograft model of minimal residual disease in MM, which approximates a human clinical condition. After intravenous injection of RPM1-8226 MM cells into immunodeficient mice, tumor cells disseminate, infiltrate bones, and induce osteolytic lesions, characteristics of MM. We will test the ability of NK3.3 EVs to prevent MM recurrence after chemotherapy treatment. Aim 1: Characterize NK3.3 EVs and establish best practices for production. We will develop optimal NK3.3 culture conditions for EV production. Proteomic and lipidomic analysis will be performed on EV preparations. NK3.3 EVs will be evaluated for killing MM cell lines and patient samples and for lack of toxicity against healthy bone marrow, peripheral blood lymphocytes and fibroblasts. Aim 2: Identify the mechanism(s) of NK EV-mediated killing. NK EVs induce caspase-mediated apoptosis. However, like NK cells, NK EVs likely kill via multiple mechanisms. We will evaluate caspase- dependent and independent killing pathways in EV-treated tumor cells. We will inhibit killing pathways by gene knockdown and chemical treatment. MM cell lines and primary tumor cells will be used to determine whether drug-resistant and CSC-like MM cells are sensitive to killing by NK3.3 EVs. Aim 3: Test the in vivo efficacy of NK3.3 EVs in preventing/delaying tumor recurrence in a murine model of minimal residual disease in MM. Different concentrations of NK EVs will be administered intravenously. Tumor dissemination will be monitored by bioluminescence imaging; bone lesions by X-ray and CT scanning. Toxicity will be assessed by analysis of body and organ weights and blood chemistry. Normal and tumor-bearing mice will be infused with labeled NK EVs to monitor biodistribution and half-life. These studies are the first step towards developing NK3.3 EVs as a treatment for MM patients who desperately need new options to improve their quality of life and prolong their survival.", "keywords": [ "3-Dimensional", "Apoptosis", "Area", "Binding", "Biodistribution", "Biological Assay", "Black American", "Blood Cells", "Blood Chemical Analysis", "Body Weight", "Bone Marrow", "Bone Pain", "Bortezomib", "Caspase", "Cell Line", "Cell Therapy", "Cells", "Cellular immunotherapy", "Characteristics", "Chemicals", "Chemoresistance", "Clinical", "Clinical Trials", "Cytolysis", "Development", "Diagnosis", "Disease", "Disease remission", "Dose", "Drug resistance", "Fibroblasts", "Fracture", "Freezing", "Frequencies", "Genes", "Goals", "Half-Life", "Hematologic Neoplasms", "Herbicides", "Human", "Immunodeficient Mouse", "In Vitro", "Infiltration", "Infusion procedures", "Intravenous", "Label", "Laboratories", "Lesion", "Lytic Metastatic Lesion", "Maintenance Therapy", "Mediating", "Membrane", "Modeling", "Molecular", "Monitor", "Multiple Myeloma", "Mus", "NK cell therapy", "Natural Killer Cells", "Normal Cell", "Organ Weight", "Osteolytic", "Pathway interactions", "Patients", "Penetration", "Peripheral Blood Lymphocyte", "Pharmaceutical Preparations", "Preparation", "Primary Neoplasm", "Process", "Production", "Proteomics", "Quality of life", "Recurrence", "Refractory", "Regimen", "Relapse", "Residual Neoplasm", "Resistance", "Risk", "Roentgen Rays", "Sampling", "Scanning", "Stable Disease", "Survival Rate", "Testing", "Time", "Toxic effect", "Tumor Burden", "Veterans", "Vietnam", "Visual", "Xenograft Model", "agent orange", "base", "bioluminescence imaging", "bone", "cancer cell", "cancer stem cell", "cancer therapy", "cell killing", "chemotherapy", "clinical development", "cohort", "cytokine release syndrome", "extracellular vesicles", "hydrogel scaffold", "improved", "in vivo", "in vivo evaluation", "innovation", "intravenous administration", "intravenous injection", "kidney dysfunction", "kidney infection", "knock-down", "lenalidomide", "lipidomics", "loss of function", "mouse model", "neoplastic cell", "novel therapeutics", "peripheral blood", "pomalidomide", "prevent", "relapse patients", "side effect", "stem-like cell", "tumor", "tumor hypoxia", "tumor microenvironment" ], "approved": true } }, { "type": "Grant", "id": "11048", "attributes": { "award_id": "1I01BX006162-01", "title": "Defining the Contribution of Mitochondrial DNA to Viral Infectious Diseases, Type 2 Diabetes, and their Interactions", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2023-01-01", "end_date": "2026-12-31", "award_amount": null, "principal_investigator": { "id": 27019, "first_name": "TODD M", "last_name": "HULGAN", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1477, "ror": "https://ror.org/05eq41471", "name": "Veterans Health Administration", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "Mitochondria are at the intersection of metabolism and immunity. Mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) variants affect mitochondrial function and diseases relevant to Veterans. This project includes a team with extensive experience studying the genetics of type 2 diabetes mellitus (T2D) and viral infectious diseases (VID). A new collaboration is proposed to define the mitochondrial genetic associations with and interactions between these two common and important phenotypes. The overarching hypothesis is that mitochondrial genetic information available in the Million Veteran Program (MVP) will be associated with T2D and VID, and will modify interactions between them. Important mechanistic connections through immune responses (both innate and adaptive) relevant for VID and T2D pathogenesis are regulated in part by mitochondria. Coronavirus disease 2019 (COVID-19) is a new VID that has infected >600,000 Veterans to date and highlights the bi-directional intersection between T2D and VID. COVID-19 includes profound immune dysregulation (particularly interferon [IFN] signaling and responses), metabolic derangements including exacerbation of T2D, and is also made more severe by these conditions. Several mitochondria-related effects of COVID-19 have already been reported. MVP genotyping currently contains 20 common and ~130 rare mtDNA variants in ~650,000 Veterans and will soon include whole genome sequencing (WGS) with more extensive mtDNA genotyping for 150,000 of these Veterans. This project will characterize, curate, and derive information from these variants in the MVP by established and novel methods to establish a new resource (“MitoMVP”) and perform new analyses. The following aims will enhance the understanding of mitochondria- related VID and T2D interactions, facilitate development of new therapeutic targets, and provide a data resource to accelerate broader mitochondria-targeted precision medicine efforts. First, MitoMVP, a curated dataset of mitochondrial genetic information in the MVP including expanded mitochondrial genetic information on quantity (mtDNA copy number) and quality (predicted pathogenicity) will be established. Next, mitochondrial genetic information and nDNA genetic variants associated with T2D and VID will be identified, and genetic interactions between them defined. Finally, phenotypic interactions between T2D and VID that influence genetic associations will be assessed through stratified analyses focused on severe COVID-19 as a prototype. Because T2D is a complex phenotype, information in the MVP will be used to define subgroups with T2D- related clinical and laboratory metabolic phenotypes (e.g., obesity, hyperglycemia, and dyslipidemia/low HDL cholesterol) for stratified analyses, potentially yielding new associations and important clues to mechanisms of gene-by-environment interactions. This aim will also include mitochondrial phenome-wide association studies (PheWAS) to identify novel genotype-phenotype associations of interest, providing additional MitoMVP information that will be available for future studies by other MVP investigators.", "keywords": [ "Accounting", "Address", "Affect", "Atlases", "Bioenergetics", "COVID-19", "COVID-19 impact", "Clinical", "Collaborations", "Communicable Diseases", "Complex", "Custom", "DNA", "Data", "Data Set", "Development", "Diabetes Mellitus", "Disease", "Dyslipidemias", "Future", "Genes", "Genetic", "Genetic Variation", "Genetic study", "Genotype", "Health", "High Density Lipoprotein Cholesterol", "Hyperglycemia", "Immune", "Immune response", "Immunity", "Infection", "Inflammation", "Innate Immune Response", "Interferon Type I", "Interferons", "Laboratories", "Link", "Measures", "Metabolic", "Metabolism", "Methods", "Mitochondria", "Mitochondrial DNA", "Non-Insulin-Dependent Diabetes Mellitus", "Nuclear", "Obesity", "Pathogenesis", "Pathogenicity", "Phenotype", "Regulation", "Reporting", "Research", "Research Personnel", "Resources", "Risk", "Signal Transduction", "Subgroup", "Variant", "Veterans", "Viral", "Virus Diseases", "Work", "data resource", "defined contribution", "diabetes risk", "disorder risk", "experience", "gene environment interaction", "genetic association", "genetic information", "genetic variant", "genome sequencing", "immune activation", "innovation", "interest", "metabolic phenotype", "new therapeutic target", "novel", "phenome", "precision medicine", "prevent", "programs", "prototype", "response", "severe COVID-19", "whole genome" ], "approved": true } }, { "type": "Grant", "id": "11085", "attributes": { "award_id": "1I21RX004409-01", "title": "Nitrite Supplementation to Mitigate Fatigability and Increase Function in Long COVID Patients", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2023-03-01", "end_date": "2025-02-28", "award_amount": null, "principal_investigator": { "id": 27057, "first_name": "Daniel E.", "last_name": "Forman", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1477, "ror": "https://ror.org/05eq41471", "name": "Veterans Health Administration", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "Prevalence of long COVID is surging among Veterans, and Veterans afflicted with this disease typically incur progressive declines in function, diminished quality of life and increased disability. Skeletal muscle pathophysiology has been implicated as a significant determinant of long COVID pathophysiology and clinical declines. Dr. Forman is a cardiologist and geriatrician who is currently engaged in research studying benefits of nitrite supplementation with investigational new drug (IND) nitrite capsule supplements in older adults with sedentariness and/or heart failure. In that work, he is focusing primarily on the utility of nitrites to increase skeletal muscle mitochondrial respiration. Secondarily, he is exploring if mitochondrial respiration changes correlate to changes in physical function. In particular, he is studying if increased serum and skeletal muscle nitrite elevations correlate to improvements in cardiorespiratory fitness (i.e., peak oxygen utilization [VO2]), and to decreased fatigability (i.e., rating of perceived exertion [RPE] during steady-state submaximal [1.5 miles per hour] walking). In this SPiRE application, Dr. Forman proposes to redirect his expertise in nitrite therapeutics to Veterans with long COVID. Nitrites will be administered as nitrate-rich beetroot juice versus nitrate-poor placebo. When beetroot juice is ingested, nitrates are metabolized to nitrite. Compared to IND nitrite capsules, beetroot juice is relatively easier to administer, less expensive, and hemodynamically safer. Whereas serum nitrite levels have not been consistently high in studies of beetroot juice interventions as compared to nitrite capsules, this proposal aims to optimize nitrite levels using 210 ml per day of Beet-It nitrate beverage (James White Drinks Ltd., Ipswich, UK) to provide 16 mmol of nitrate/day for 14 days versus a 210 ml of nitrate- depleted placebo. All participants will also undergo physical therapy. Endpoints in this SPiRE study are oriented principally to physical function. Endpoints (measured pre- and post- the 2-week intervention) include fatigability as well as walking efficiency (VO2/kg) during steady-state walking. Furthermore, traditional functional indices of peak VO2, VO2 at anaerobic threshold, 6-minute walk distance, short physical performance battery, and pulmonary function tests will also be assessed. Nitrite levels (both serologically and in the skeletal muscle itself) will be measured to best ascertain the relationship of nitrite and putative clinical changes. In addition, analyses of skeletal muscle will clarify if nitrite-mediated changes in physical function correlate to changes in skeletal muscle respiration. Overall, this proposal aligns with the Veteran’s Affairs Office of Research and Development’s commitment to research that helps Veterans affected by COVID-19, and it also aligns with the Rehabilitation Research and Development’s mission to maximize Veterans’ functional independence, quality of life and participation in their lives and community. Dr. Forman anticipates applying the data and momentum from this compelling SPiRE-based analysis to pursue a subsequent MERIT trial that reinforces the value of nitrite therapeutics more definitively for long COVID patients.", "keywords": [ "Acute", "Address", "Adult", "Aerobic", "Amino Acids", "Anaerobic Threshold", "Arginine", "Beverages", "COVID-19", "COVID-19 impact", "COVID-19 patient", "Chronic Obstructive Pulmonary Disease", "Citrulline", "Clinical", "Communities", "Consumption", "Data", "Diet", "Disease", "Elderly", "Exercise", "Exertion", "Fatigue", "Foundations", "Functional disorder", "Health Care Costs", "Healthcare", "Healthcare Systems", "Heart failure", "Hour", "Ingestion", "Intervention", "Investigational Drugs", "Ischemia", "Juice", "Lead", "Left", "Long COVID", "Measures", "Mediating", "Mission", "Mitochondria", "Muscle Mitochondria", "Myalgia", "Nitrates", "Nitric Oxide", "Nitrites", "Oxygen", "Participant", "Personal Satisfaction", "Physical Function", "Physical Performance", "Physical therapy", "Physiological", "Placebos", "Plants", "Prevalence", "Principal Investigator", "Pulmonary function tests", "Quality of life", "Randomized Controlled Trials", "Regimen", "Rehabilitation therapy", "Research", "Residual state", "Respiration", "Risk", "SARS-CoV-2 infection", "Serology", "Serum", "Shortness of Breath", "Signal Transduction", "Signaling Molecule", "Skeletal Muscle", "Source", "Standardization", "Stress", "Supplementation", "Survivors", "Symptoms", "Therapeutic", "Therapeutic Uses", "United States Department of Veterans Affairs", "Veterans", "Walking", "Work", "capsule", "cardiorespiratory fitness", "coronavirus disease", "design", "disability", "efficacy study", "exercise regimen", "functional decline", "functional independence", "hemodynamics", "improved", "indexing", "innovation", "novel", "patient population", "post SARS-CoV-2 infection", "primary endpoint", "programs", "pulmonary function", "randomized placebo controlled trial", "rehabilitation research", "research and development", "research study", "sedentary", "young adult" ], "approved": true } }, { "type": "Grant", "id": "11187", "attributes": { "award_id": "1R13HS029438-01", "title": "National Practice-Based Research Network Conferences 2023 to 2025", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 27199, "first_name": "Patrick", "last_name": "O'Malley", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-04-01", "end_date": "2026-03-31", "award_amount": 50000, "principal_investigator": { "id": 27200, "first_name": "Allison", "last_name": "Cole", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1995, "ror": "", "name": "NORTH AMERICAN PRIMARY CARE RES GROUP", "address": "", "city": "", "state": "KS", "zip": "", "country": "United States", "approved": true }, "abstract": "The North American Primary Care Research Group proposes promoting, convening, coordinating, managing, evaluating, and disseminating the results of the 19th, 20th, and 21st meetings of the Practice- Based Research Networks (PBRNs) in the summers of 2023, 2024 and 2025. With a projected attendance of 125, the purpose of the annual two-day conference will be to build on the skills and knowledge of clinicians, researchers, and community partners in evidence-based research to improve the health of the U.S. population, healthcare delivery systems, and the quality of primary health care. Along with sharing translatable insights emanating from research, the conference will link research with clinical practice– especially primary care practice—by facilitating collaboration among conference attendees, policymakers, and funders. The Agency for Healthcare Research and Quality (AHRQ) support for the PBRN conferences help in achieving the goal of improving health care for all Americans, including the priority populations. The conference allows practitioners to acquire the necessary evidence, interventions, and dissemination to make better decisions and deliver exceptional, accessible, equitable, affordable, and patient-centered health care. NAPCRG has successfully hosted the 2012-2022 PBRN conferences, including 2 virtual conferences due to COVID-19, and attracted an average of 140 attendees. With input from a Steering Committee (SC) experienced with PBRNs and prior PBRN conferences, each year, NAPCRG will select a conference theme and plenary speakers and select papers, workshops, and poster presentations through a call for abstracts. Conference sessions will address the science of research and operation of PBRNs and provide for presentation of studies focusing on practice and quality improvement, COVID-19, behavioral health, patient safety, health information technology/electronic health records, telemedicine, and issues in primary care practice, and prevention. NAPCRG will manage all conference logistics—including a call for abstracts, conference promotion, registration, continuing education accreditation, conference evaluation, and social media strategy. The proposed conferences will provide skill-building, knowledge transfer, brainstorming future research agendas, collaboration, and outcomes to a diverse mix of stakeholders.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "11192", "attributes": { "award_id": "1R03HS029422-01", "title": "Design, Analysis, and Optimization of Equitable and Value-based Baseline Testing Policies for Sports-Related Concussion", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 27209, "first_name": "Nora", "last_name": "Mueller", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-04-01", "end_date": "2025-03-31", "award_amount": 48747, "principal_investigator": { "id": 27210, "first_name": "Gian-gabriel", "last_name": "Garcia", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1578, "ror": "https://ror.org/01zkghx44", "name": "Georgia Institute of Technology", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "This goal of this project is to design and optimize an equitable and value-based approach to baseline testing for sports-related concussion by synthesizing machine learning and systems science methods. Concussion, one of the most common types of traumatic brain injury, afflicts upwards of 3.6 million people annually and is a major public health issue. Timely and effective concussion management is considered a major factor in mitigating both short-term and long-term consequences of the injury. Baseline testing is a widely used practice that provides physicians and athletic trainers a reference point indicating someone’s “normal” performance across several concussion-specific functional domains. Baseline testing is also a resource-intensive process, requiring specific expertise in the time-consuming administration of a multi-dimensional concussion assessment battery; nevertheless, baseline testing is considered essential to the injury management process for those at elevated risk of concussion, including student-athletes and military personnel. Despite widespread use of baseline testing, there is a lack of evidence-based guidance on who should be prioritized for baseline testing in resource-limited environments. The multidisciplinary research team aims to address this knowledge gap by synthesizing machine learning and systems science methods with data from the Concussion Assessment, Research, and Education Consortium – one of the largest multi-site datasets available on sports-related concussion. Specifically, the project aims to first use interpretable machine learning methods and statistical modeling to estimate the diagnostic utility of baseline testing in a heterogeneous cohort of student-athletes. Next, the project aims to design a decision- analytic model that can optimally allocate baseline tests. This model will take into account: (1) personalized estimates for the diagnostic utility of baseline tests, (2) individualized risk for sport-related concussion, (3) resource constraints at a given institution, and (4) equity considerations in the allocation of baseline tests. This research can transform how clinicians, athletic trainers, and other trained medical staff approach baseline testing and concussion diagnosis for those who may be under-represented in the development of existing clinical guidelines, leading to more timely and accurate diagnosis of concussion. Moreover, resources saved through an efficient allocation of baseline tests can be reallocated to other valuable tasks performed by specialized medical personnel, including other tasks along the concussion care continuum, heat illnesses prevention, and COVID-19 screening.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1384, "pages": 1392, "count": 13920 } } }